Myriad Genetics (NASDAQ:MYGN)‘s stock had its “hold” rating reaffirmed by analysts at Barclays in a research report issued to clients and investors on Monday, January 8th. They currently have a $30.00 price objective on the stock. Barclays’ price objective indicates a potential downside of 16.18% from the company’s previous close.
Other equities research analysts have also recently issued research reports about the stock. Cowen reaffirmed a “hold” rating and issued a $25.00 price target on shares of Myriad Genetics in a report on Sunday, September 17th. Leerink Swann reaffirmed a “market perform” rating and issued a $31.00 price target on shares of Myriad Genetics in a report on Monday, October 2nd. Deutsche Bank lifted their price target on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Wednesday, November 8th. Stephens set a $45.00 target price on shares of Myriad Genetics and gave the company a “buy” rating in a report on Wednesday, January 3rd. Finally, ValuEngine cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the stock. Myriad Genetics currently has an average rating of “Hold” and a consensus price target of $30.09.
Myriad Genetics (NASDAQ MYGN) traded down $0.26 during trading hours on Monday, hitting $35.79. 1,073,900 shares of the company were exchanged, compared to its average volume of 567,490. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.34 and a quick ratio of 2.06. The company has a market cap of $2,510.00, a PE ratio of 24.18, a PEG ratio of 2.29 and a beta of 0.24. Myriad Genetics has a 52 week low of $15.15 and a 52 week high of $37.30.
Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.05. The company had revenue of $190.20 million for the quarter, compared to analysts’ expectations of $183.52 million. Myriad Genetics had a net margin of 13.28% and a return on equity of 9.54%. Myriad Genetics’s revenue was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.23 EPS. sell-side analysts anticipate that Myriad Genetics will post 1.05 EPS for the current year.
In other Myriad Genetics news, insider Alexander Ford sold 3,031 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $31.64, for a total transaction of $95,900.84. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Richard M. Marsh sold 13,759 shares of the business’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $36.25, for a total transaction of $498,763.75. Following the transaction, the vice president now owns 136,385 shares of the company’s stock, valued at $4,943,956.25. The disclosure for this sale can be found here. Insiders have sold a total of 30,290 shares of company stock worth $1,044,590 in the last three months. Insiders own 6.70% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. CS Mckee LP grew its position in shares of Myriad Genetics by 0.3% during the 2nd quarter. CS Mckee LP now owns 30,000 shares of the company’s stock valued at $775,000 after purchasing an additional 100 shares in the last quarter. Public Employees Retirement System of Ohio grew its position in shares of Myriad Genetics by 1.0% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 143,036 shares of the company’s stock valued at $3,696,000 after purchasing an additional 1,480 shares in the last quarter. TrimTabs Asset Management LLC grew its position in shares of Myriad Genetics by 17.2% during the 3rd quarter. TrimTabs Asset Management LLC now owns 11,798 shares of the company’s stock valued at $427,000 after purchasing an additional 1,728 shares in the last quarter. Riverhead Capital Management LLC grew its position in shares of Myriad Genetics by 80.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 4,161 shares of the company’s stock valued at $107,000 after purchasing an additional 1,861 shares in the last quarter. Finally, Stifel Financial Corp grew its position in shares of Myriad Genetics by 3.6% during the 3rd quarter. Stifel Financial Corp now owns 54,408 shares of the company’s stock valued at $1,968,000 after purchasing an additional 1,900 shares in the last quarter.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/17/myriad-genetics-mygn-stock-rating-reaffirmed-by-barclays.html.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.